Hicks Derek has filed 7 insider transactions across 1 company since January 2023.
Most recent transaction: a sale of 6502 shares of Intellia Therapeutics, Inc. ($NTLA) on January 03, 2025.
Activity breakdown: 0 open-market purchases and 3 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 3, 2025 | Intellia Therapeutics, Inc. | $NTLA | Hicks Derek | EVP, Chief Business Officer | S | Common Stock | 6502 | $12.18 | 59,878.0000 | 0 | 9.80% | 0.00% |
| March 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | Hicks Derek | EVP, Chief Business Officer | A | Common Stock | 29393 | $0.00 | 66,380.0000 | 0 | 79.47% | 0.00% |
| March 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | Hicks Derek | EVP, Chief Business Officer | A | Stock Option (right to buy) | 42421 | $0.00 | 42,421.0000 | 0 | 9999.99% | 0.00% |
| Jan. 3, 2024 | Intellia Therapeutics, Inc. | $NTLA | Hicks Derek | EVP, Chief Business Officer | S | Common Stock | 3877 | $29.46 | 36,987.0000 | 0 | 9.49% | 0.00% |
| March 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | Hicks Derek | EVP, Chief Business Officer | A | Common Stock | 23558 | $0.00 | 40,864.0000 | 0 | 136.13% | 0.00% |
| March 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | Hicks Derek | EVP, Chief Business Officer | A | Stock option (right to buy) | 33287 | $0.00 | 33,287.0000 | 0 | 9999.99% | 0.00% |
| Jan. 4, 2023 | Intellia Therapeutics, Inc. | $NTLA | Hicks Derek | EVP, Chief Business Officer | S | Common Stock | 1812 | $37.21 | 17,306.0000 | 0 | 9.48% | 0.00% |